OncoAlert

The OncoAlert 🚨Newsletter NOW OUT Covering July 12-18, 2024 REGISTER at www.Oncoalert360.com or https://lnkd.in/d7QR5f-6 Discussing: ✅Industry update on ARANOTE #ProstateCancer ✅IMPASSION132 in #BreastCancer by Rebecca Dent Dr. Javier Cortés Castán ✅Panther Trial 🇸🇪in #BreastCancer by Alexios Matikas Theodoros Foukakis ✅HR+ BC in Young Women Review by Aleix Prat MD, PhD ✅Multiorgan Immune related AEs from ICI's🏁 ✅RAS/RAF landscape in Monoclonal Plasma Cell Conditions #MultipleMyeloma ✅Sotorasib 💊for Vascular Malformations associated w/KRAS g12C🧬 ✅Low Sodium 🧂and ICI's 🏁 Emre Yekeduz Yüksel ÜRÜN and much more

The OncoAlert 🚨Newsletter NOW OUT Covering July 12-18, 2024 REGISTER at www.Oncoalert360.com or https://lnkd.in/d7QR5f-6 Discussing: ✅Industry update on ARANOTE #ProstateCancer https://lnkd.in/gVwJMRgt ✅IMPASSION132 in #BreastCancer https://lnkd.in/gd3AiQKm Rebecca Dent Dr. Javier Cortés Castán ✅Panther Trial 🇸🇪in #BreastCancer https://lnkd.in/gDkj3vDB Alexios Matikas Theodoros Foukakis ✅Impact of EML4-ALK variants and co-occurring TP53 mutations on duration of first-line ALK tyrosine kinase inhibitor treatment and overall survival in ALK fusion–positive #NSCLC 🫁 https://lnkd.in/gzHbcYqx ✅Out-of-pocket costs for diagnostic testing following abnormal prostate cancer screening among privately insured men. American Cancer Society Journals https://lnkd.in/gKKY3X8z ✅Sotorasib 💊for Vascular Malformations associated w/KRAS g12C🧬by https://lnkd.in/gjq_C9d7 ✅Multiorgan Immune related AEs from ICI's🏁 https://lnkd.in/g4Me2Vxp ✅Low Sodium 🧂and ICI's 🏁by Emre Yekeduz Yüksel ÜRÜN Beliz Bahar Karaoğlan https://lnkd.in/gFUfbvUy ✅Immunotherapy approach shows potential in some people with metastatic solid tumors https://lnkd.in/eeDisqt9 https://lnkd.in/eHBPaZy7 Prof. Dr. Axel S. Merseburger Neeraj Agarwal, MD, FASCO Matteo Lambertini Icro Meattini

Following the presentation of the results at #ESMOBreast24, the long-term efficacy outcomes of the #PANTHER trial are now published at The Journal of Clinical Oncology! #breastcancer #SweBCG, #GBG, #ABCSG, Karolinska University Hospital, Karolinska Institutet, OncoAlert

Just out on NEJM by Guillaume Canaud 🇫🇷and team Sotorasib for Vascular Malformations Associated with KRAS G12C Mutation Sotorasib,💊 a KRAS G12C inhibitor🧬 ➡️effectively reduced vascular malformation size and improved symptoms in both mouse models and human patients with KRAS G12C–related arteriovenous malformations Suggesting it as a promising treatment option. publication link in comments antoine Fraissenon Bayard Charles Gabriel MORIN Sanela Protić Lola Zerbib Sophia Ladraa thomas blauwblomme Olivier Naggara Michael Duruisseaux Clothilde Boitel sophie kaltenbach Estelle Balducci Patrick Villarese Vahid Asnafi Annouk Bisdorff Bresson

Just Out on @EurUrolOncol 🚨 Study investigated the association of clinical factors at presentation with unsampled high-risk #ProstateCancer & mortality outcomes following radical prostatectomy in patients with biopsy Gleason1⃣ ➡️These findings suggest maintaining the "cancer" classification for Gleason's 1⃣ patients with these clinical factors and considering rebiopsy to identify high-grade disease, which could help minimize mortality risks. ⭐️However, the study's single-institution cohort design might limit its generalizability Link to article in comments Derya Tilki

New Cellular Immunotherapy Approach Shows Promise in some Solid Tumors NIH🇺🇸Researchers genetically🧬 engineered lymphocytes from each patient to produce receptors targeting 🎯their specific cancer cells ➡️In patients with metastatic #ColorectalCancer, this personalized immunotherapy🧪 shrank tumors and prevented regrowth for up to seven months (Although a small study) As part of a larger 2⃣ trial, seven patients were treated, with three showing substantial shrinkage of metastatic tumors in the liver, lung, and lymph nodes that lasted for four to seven months Link to publication in Nature https://lnkd.in/eHBPaZy7 Link to NCI Press Release https://lnkd.in/eeDisqt9

The OncoAlert 🚨Newsletter NOW OUT Covering July 5-11. 2024 REGISTER at http://Oncoalert360.com or https://lnkd.in/d7QR5f-6 Discussing: ✅UNICANCER-PRODIGE23🧪 in #RectalCancer ✅Renal function after SABR in 1ry #KidneyCancer Alex Louie Shankar Siva ✅Resistance Oncogenic KRASinh #PancreaticCancer ✅PDL1& Nectin4 expression in #BladderCancer out on ✅Resistance of EGFR TKIs #LungCancer #NSCLC 🫁 ✅SWOG1216 🇺🇸 Neeraj Agarwal, MD, FASCO ✅Dose Relation of Exercise & Distant Recurrence in 1ry #BreastCancer🏃♀️ Benedikt Westphalen Allison Rosen, MS Cathy Eng Sharlene Gill MD, MPH, MBA, FRCP(C), FASCO Matteo Lambertini Henning Willers, MD, FASTRO Sean McBride Petros Grivas Andrea Apolo Sumanta Pal, MD, FASCO Prof. Dr. Axel S. Merseburger Enrique Grande Hidehito Horinouchi Eric Singhi Biagio Ricciuti Janice Cowden Jill Feldman

Just out on our @AmericanCancer partner journal @JournalCancer 🚨 by Dipesh Uprety & team Survival trends among patients with metastatic non–small cell lung cancer before and after the approval of immunotherapy in the United States🇺🇸 Study assessed survival outcomes in patients with advanced #NSCLC 🫁before and after the introduction of immunotherapy 🧪focusing on OS and cancer-specific survival using data from the Surveillance, Epidemiology, and End Results database spanning 2000 to 2020. ➡️The analysis revealed significantly improved OS and cancer-specific survival rates in the immunotherapy era (2015–2020) compared to the preimmunotherapy era (2010–2014). ✅Specifically: 1-year OS improved from 33.5% to 40.1% 3-year OS from 11.7% to 17.8% 5-year OS from 6.8% to 10.7%. These findings underscore the substantial survival benefits observed since the approval of nivolumab, marking a significant advancement in the treatment landscape for metastatic NSCLC. Link to article in comments Pinging OncoAlert Lung Cancer faculty Christian Rolfo, MD, PhD, MBA,Dr.h.c. GILBERTO de lima LOPES Junior Stephen Liu Peters Solange Bartomeu Massuti Marina Chiara Garassino Umberto Malapelle Charu Agrawal Christine M. Lovly, MD, PhD Jill Feldman Vanita Noronha Jarushka Naidoo Terri Conneran Hidehito Horinouchi Eric Singhi

Just out from Swedish🇸🇪Colleagues at Linköping University Prediction models of persistent taxane-induced peripheral neuropathy among #BreastCancer survivors using whole-exome sequencing 🧬 Persistent taxane🧪induced peripheral neuropathy🧠 (TIPN) significantly affects the quality of life in early-stage breast cancer survivors (ESBCS). ➡️To predict the risk of persistent TIPN symptoms, researchers developed and validated polygenic prediction models using logistic regression, incorporating clinical risk factors. Out of 337 whole-exome sequenced ESBCS, two models predicting individual PN symptoms demonstrated AUC results above 6⃣0⃣% in validation. Specifically, the numbness in feet model, with 35 single nucleotide variants (SNVs), correctly predicted 73% of cases, while the tingling in feet model, with 55 SNVs, had a 70% prediction accuracy. Both models featured SNVs from genes like ADAMTS20, APT6V0A2, and SCN10A. However, models for other symptoms such as cramps, difficulty climbing stairs, and difficulty opening a jar did not validate successfully. ✅These findings suggest that polygenic models can effectively estimate the risk of certain persistent TIPN symptoms in Early Stage Breast #Cancer Survivors  Hanna Uvdal,  Elisabeth Avall Lundqvist & Henrik Gréen

Dendritic Cell–Based Immunotherapy in Patients With Resected #pancreaticCancer (Out on JCO) Study aimed to evaluate the efficacy of dendritic cell (DC)-based immunotherapy in preventing the recurrence of pancreatic cancer. Conducted as a single-center, open-label, single-arm phase I/II trial, it included patients who had undergone resection and completed standard-of-care treatment without recurrent disease. Patients received autologous DCs pulsed with allogeneic mesothelioma tumor cell lysate antigens. Of the 38 patients analyzed: ➡️74% completed the study protocol with five vaccinations. After a median follow-up of 25.5 months: ✅ 2-year recurrence-free survival (RFS) rate was 64%, meeting the primary endpoint of ≥60%. ✅Vaccination led to increased circulating activated CD4+ T cells and immune responses in vitro, with T-cell receptor-sequencing showing vaccine-specific T cells in a resected lung metastasis Link to publication in comments Marcella Verbakel-Willemsen Sjoerd van der Burg Thierry P.P. van den Bosch, PhD Martijn Kolijn Anton LANGERAK, Miranda Moskie Elise van der Oost Nina Rozendaal,  Sara Baart Joachim Aerts,  Casper van Eijck